Received August 02, 2022
Accepted February 21, 2023

Objective: Follicle-stimulating hormone (FSH) is essential for folliculogenesis and acts through the Follicle Stimulating Hormone Receptor (FSHR) that is present on the membrane of granulosa cells. Polymorphisms in the FSHR gene may lead to an altered pattern of receptor expression on the cell surface or to changes in affinity for FSH. The aim of this prospective study was to identify with there is an association between Follicle Stimulating Hormone Receptor (FSHR) gene Ala307Thr polymorphism(rs6165) and ovarian reserve, ovarian response or clinical results in IVF/ICSI treatment. Methods: This prospective cohort study included 450 women who underwent IVF/ICSI cycles. DNA was extracted from peripheral blood, and the Ala307Thr FSHR polymorphism(rs6165) was genotyped using TaqMan SNP genotyping assay. Participants were divided into three groups according to their Ala307Thr FSHR genotype: Thr/Thr (n:141), Thr/Ala (n = 213) and Ala/Ala (n = 96). The results were associated with age, anti-Müllerian hormone (AMH) levels, antral follicle counts (AFC), total dose of r-FSH, follicle size, number of retrieved oocytes, and clinical outcome of IVF/ICSI cycles. The statistical analyses were performed using Fisher’s exact test and Kruskal-Wallis test. Results: An association between the genotypes of the FSHR (Ala307Thr) polymorphism and different doses of r-FSH was observed. Patients with the Ala/Ala genotype received a higher r-FSH dose than patients with the Ala/Thr (p=0.0002) and Thr/Thr (p=0.02) genotypes. No other correlation was observed. Conclusion: Ala/Ala genotype was associated with the use of higher doses of recombinant FSH(r-FSH), suggesting that homozygosis of this allelic variant (Ala) provides lower sensitivity to r-FSH.